gastrointestinal oncology
- Health
Daraxonrasib Phase 3 Results: PDAC Survival Gains
The RASolute 302 trial data on daraxonrasib Phase 3 results reveals a significant breakthrough in metastatic PDAC survival rates.
The RASolute 302 trial data on daraxonrasib Phase 3 results reveals a significant breakthrough in metastatic PDAC survival rates.